Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aprea Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
APRE
Nasdaq
8731
https://www.aprea.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aprea Therapeutics Inc
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
- Apr 10th, 2024 4:00 pm
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Mar 26th, 2024 11:45 am
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
- Mar 11th, 2024 12:30 pm
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
- Mar 11th, 2024 12:29 pm
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
- Mar 5th, 2024 9:45 pm
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
- Feb 6th, 2024 1:01 pm
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
- Jan 30th, 2024 1:00 pm
Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?
- Jan 10th, 2024 11:43 am
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
- Jan 4th, 2024 9:05 pm
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
- Nov 9th, 2023 9:05 pm
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
- Oct 24th, 2023 12:00 pm
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
- Oct 16th, 2023 12:30 pm
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Sep 19th, 2023 12:00 pm
Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors
- Sep 11th, 2023 12:00 pm
Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 8:05 pm
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
- Aug 24th, 2023 11:30 am
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
- Aug 10th, 2023 11:30 am
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
- Jun 14th, 2023 12:00 pm
Aprea Therapeutics to Present at BIO International Convention
- May 30th, 2023 12:30 pm
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
- May 15th, 2023 8:05 pm
Scroll